A phase 2 trial of Reata Pharmaceuticals’ omaveloxolone in patients with Friedreich’s ataxia has met its primary endpoint. The positive result, which surprised analysts, tees Reata up to file for FDA approval of the activator of Nrf2 and expand development to other neurodegenerative diseases.
